CAR-T cell therapy awareness: what behavioral signals reveal about patient readiness
Most CAR-T eligible patients never reach a treatment center. Behavioral signals captured weeks before clinical referral reveal who is actively researching cell therapy, what barriers they perceive, and whether they are ready to pursue treatment. Cancer immunotherapy behavioral intelligence closes the gap between eligibility and access.
Fewer than 20% of patients eligible for CAR-T cell therapy ever receive it. The FDA has approved six CAR-T products since 2017, yet treatment volumes remain stubbornly low relative to the eligible population. The bottleneck is not manufacturing capacity or clinical efficacy. It is awareness, readiness, and the structural friction that separates a qualifying diagnosis from an infusion chair.
Behavioral data tells us where that friction lives.
What are the markers for CAR T-cell therapy?
CAR-T cell therapy targets specific antigens on the surface of cancer cells. The most common marker is CD19, expressed on B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). Newer approvals target BCMA (B-cell maturation antigen) for multiple myeloma. Eligibility depends on the presence of these markers, confirmed through flow cytometry, immunohistochemistry, or molecular testing.
But marker presence alone does not determine who gets treated. A patient must first know that CAR-T exists, understand they may qualify, and navigate referral to a certified treatment center. Each of those steps generates behavioral signals long before any clinical record is updated.
Which criteria must a patient meet to receive CAR T-cell therapy?
Beyond antigen expression, patients typically must have relapsed or refractory disease after two or more prior lines of therapy. They need adequate organ function, an ECOG performance status of 0 or 1, and access to an authorized treatment center, most of which are academic medical centers concentrated in metropolitan areas.
Geographic access is a filter that eliminates patients silently. A patient in rural Mississippi searching "CAR-T therapy near me" at 2 a.m. is generating a signal that no EHR captures. That search tells us the patient is aware, motivated, and potentially blocked by distance. VIOLET captures these behavioral patterns and maps them against SDOH data to identify populations that are eligible but underserved.
What behavioral signals reveal about readiness
Patient readiness for CAR-T is not binary. It exists on a spectrum, and behavioral data maps that spectrum with precision that clinical records cannot match.
Early-stage signals include searches for "immunotherapy vs chemotherapy," "what happens when chemo stops working," and "clinical trials for lymphoma." These indicate a patient or caregiver exploring options but not yet committed to a specific therapy.
Mid-stage signals shift to queries like "CAR-T side effects," "how long does CAR-T treatment take," and "CAR-T therapy cost." These show someone actively evaluating CAR-T as a realistic option, weighing risks and logistics.
Late-stage signals are specific and actionable: "CAR-T centers in [city]," "how to get referred for CAR-T," "CAR-T insurance coverage." These patients are ready. They need a path, not more information.
VIOLET classifies these behavioral stages and scores them alongside clinical and demographic data to produce a readiness profile. This is what we mean by cancer immunotherapy behavioral intelligence: the ability to see where a patient sits on the decision curve before they ever call a clinic.
How do you know if CAR T-cell therapy is working?
Response assessment typically occurs 28 to 90 days after infusion using PET-CT imaging. Complete response rates vary by indication but range from 40% to 54% for DLBCL and up to 80% for pediatric ALL. Patients and caregivers search for response indicators heavily during this window, generating a second wave of behavioral data that reflects anxiety, hope, and information need.
Post-treatment behavioral signals matter for pharma companies monitoring real-world outcomes and for health systems managing follow-up care. Search patterns around "CAR-T relapse signs" or "life after CAR-T" reveal unmet information needs that current patient education programs fail to address.
What is one major side effect of CAR-T therapy?
Cytokine release syndrome (CRS) is the most significant and common side effect of CAR-T therapy, occurring in 50% to 90% of patients depending on the product and disease. CRS can range from mild fever to life-threatening multiorgan dysfunction. It is also the side effect patients search for most before and after treatment.
Search volume for "cytokine release syndrome symptoms" spikes in geographic clusters that correlate with treatment center locations. This correlation helps validate that behavioral data accurately reflects real clinical activity, not just casual browsing.
Key statistics
CAR-T therapy data and behavioral intelligence produce measurable patterns:
Why CAR-T therapy data needs a trust layer
Behavioral signals are only useful if the data underneath them is reliable. A search pattern means nothing if the demographic, geographic, or clinical data it maps against is outdated, incomplete, or unconsented.
SuperTruth's Data Trust Index scores every health data record from 0 to 100 across eight dimensions. Provenance carries 25% of the weight because knowing where data came from determines whether it can be used for patient identification, clinical trial matching, or pharma campaign targeting. Consent carries 20% because behavioral data used without proper governance creates regulatory exposure that no insight is worth.
For CAR-T specifically, cell therapy patient awareness data must meet a higher standard. These patients are vulnerable, often late in their treatment arc, and making decisions under extreme pressure. The data that informs outreach to them should be scored, validated, and governed.
From signals to action
The gap between CAR-T eligibility and treatment is not a clinical problem. It is a data problem. Patients are searching. They are ready at different stages. And the signals they generate can guide pharma outreach, health system referral pathways, and payer authorization processes, but only if someone is watching the right layer.
VIOLET watches that layer. It maps behavioral signals against trusted, scored health data to identify which populations are aware, which are ready, and which are blocked by barriers that better data infrastructure can remove.
To explore how CAR-T therapy data and behavioral intelligence apply to your oncology strategy, contact Louis Simeonidis, SVP Commercial Operations, at louis@supertruth.ai or (215) 918-4140.
Further reading:
Jason Alan Snyder
Co-founder of SuperTruth and Artists & Robots, and an inventor on the Data Trust Index patents. Twenty-plus years building technology inside Interpublic Group. He writes here nearly every day on data trust, provenance, and what AI should be allowed to act on, and publishes essays on his Substack.
About SuperTruth · LinkedIn · Substack · jasonalansnyder.com
See it in practice
750+ cancer search terms. Live in production.
VIOLET maps behavioral signals 12–18 months before clinical presentation.